Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX

The Oncologist(2024)10.1093/oncolo/oyad315Source: DataRank Database

A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX is a research paper published in The Oncologist (2024). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.91)OA: goldTopics (48)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Michael May ORCID,Alexander G. Raufi ORCID,Lyndon Luk ORCID,Winston Wong,Prabhjot S. Mundi ORCID

Live enrichment

PubMed:38394390 PMC:PMC10994267 OpenAlex:https://openalex.org/W4392091869

National Cancer Institute

Grant: R38 CA231577

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: T32 CA203703

FWCI

0.91

Citation Percentile

0.8%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyad315/56749111/oyad315.pdf

publisherhttps://academic.oup.com/oncolo/advance-article-pdf/doi/10.1093/oncolo/oyad315/56749111/oyad315.pdf

publisherhttps://academic.oup.com/oncolo/article-pdf/29/4/350/57210466/oyad315.pdf

journalhttps://doi.org/10.1093/oncolo/oyad315

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38394390

Fields of Study

PARP inhibition in cancer therapyPancreatic and Hepatic Oncology ResearchDNA Repair MechanismsHumansAntineoplastic Combined Chemotherapy ProtocolsAdenocarcinomaPancreatic NeoplasmsCancer SurvivorsBRCA2 ProteinBRCA1 ProteinIrinotecanOxaliplatinLeucovorinFluorouracil

MeSH Terms

Cancer SurvivorsIrinotecanOxaliplatinAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsLeucovorinFluorouracilHumansPancreatic NeoplasmsBRCA1 ProteinBRCA2 Protein

Keywords

PALB2FOLFIRINOXSomatic cellPancreatic cancerMedicineDNA Damage RepairCancer researchPoly ADP ribose polymeraseOncologyGermline mutationHomologous recombinationAdenocarcinomaInternal medicinePARP inhibitorMutationCancerGeneDNA repairBiologyGeneticsOxaliplatinPrecision MedicineHomologous Recombination Deficiency

Sustainable Development Goals

SDG 0: Good health and well-being